Ziftomenib
Highest phase reached
Phase 1
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 1
- Drug type
- Small molecule
- Drug name
- Ziftomenib
- Molecular weight
- 717.89
- Structure (SMILES)
- CNc1nc(NC2CCN(Cc3ccc4c(cc(C#N)n4C[C@H](C)N4CCN(S(C)(=O)=O)CC4)c3C)CC2)c2cc(CC(F)(F)F)sc2n1
- ko 539
- Ko 539
- Ko-539
- KO-539
- ko539
- KO539
- komzifti
- KOMZIFTI
- menin mixed lineage leukemia protein protein interaction inhibitor ko 539
- Menin-Mixed Lineage Leukemia Protein-Protein Interaction Inhibitor KO 539
- ziftomenib
- Ziftomenib
- Ziftomenib [INN]
- Ziftomenib [USAN]
- Ziftomenib [WHO-DD]
- ziftomenib inn
- ziftomenib usan
- ziftomenib who dd
- CAS registry numbers
- 2134675-36-6
- ChEMBL ID
- CHEMBL5095038
- InChIKey
- BGGALFIXXQOTPY-NRFANRHFSA-N
- PubChem compound IDs
- 138497449
- RxNorm IDs (RxCUI)
- 2725985
- FDA ingredient codes (UNII)
- 4MOD1F4ENC
- Patents
- 8
- Designations
- 7
- Earliest recorded loss of exclusivity
- 16 Jul 2044
- First in class
- No
- Fast track
- Yes
- Breakthrough designation
- Yes
- Orphan designation
- No
- Priority review
- Yes
- Orphan exclusivity
- No
- Accelerated approval
- No
- Pharmacology name
- ziftomenib
- Type
- Synthetic organic
- Drug name stem
- -menib
- Approval recorded by Guide to Pharmacology
- Yes
- Condition
- Leukemia, Myeloid, Acute
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000222
- Subject identifier
- D015470
- Condition
- Leukemia
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000565
- Subject identifier
- D007938
- Condition
- Leukemia, Lymphoid
- Highest recorded phase
- 1
- Condition identifier
- EFO:0004289
- Subject identifier
- D007945
- Condition
- Leukemia, Biphenotypic, Acute
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0019460
- Subject identifier
- D015456
- Condition identifier
- EFO_0000222
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004643
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004967
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005059
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0010643
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0011719
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0015667
- Condition identifier
- MONDO_0015667
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0018874
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0020743
- Highest recorded phase
- 1
- NCT04067336
- NCT05848687
- NCT06376162
- NCT06440135
- NCT06448013
- Hydrogen bond acceptors
- 11
- Hydrogen bond donors
- 2
- Polar surface area
- 122.42
- Calculated partition coefficient (ALogP)
- 5.01
- Calculated partition coefficient (XLogP)
- 5.6
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 3
- Rotatable bonds
- 10
- Heavy atoms
- 49
- Molecular formula
- C33H42F3N9O2S2
- Monoisotopic mass
- 717.28549845
- Natural product
- No
- 84696-200
- Recorded assays
- 60
- Active assays
- 4
Active assay types
- Confirmatory
Related records
Trials (16)
- A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia
- A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia
- A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias
- A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia
- Expanded Access to Ziftomenib
- First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
- Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia
- Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
- Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML
- Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
- Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
- Ziftomenib Maintenance Post Allo-HCT
In development for (4)
- Acute leukemia of ambiguous lineage Phase 1
- Acute myeloid leukemia Phase 1
- Leukemia Phase 1
- Lymphoid leukemia Phase 1
Other linked conditions (1)
- Acute myeloid leukemia by FAB classification